Press Releases for ONTY

Press Releases
Mentor Capital Cancer Index Start Oversubscribed
Mentor Capital Takes Investment Position in Each of 10 Cancer Immunotherapy Index Companies
Mentor Capital's Cancer Immunotherapy Index Closes 2009 with 85% Annualized Gains
Mentor Capital Announces Plan for New 2010 Actively Managed Cancer Immunotherapy Index and 45 Day Call on C Warrants for CI Index Seed Funding
Mentor Capital Cancer Immunotherapy Index Improves at a 320% Annualized Rate for Quarter
Mentor Capital Cancer Immunotherapy Index Posts Second 20% Plus Monthly Gain Lead By ImmunoCellular Therapeutics
Oncothyreon to present at BioCentury NewsMakers Conference
Oncothyreon to present at Rodman & Renshaw Global Healthcare Conference
New Cancer Immunotherapy Index Posts 23% Gains Lead By Mentor Capital, Inc. And Oncothyreon
BenchmarkJournal.Com Free Analyst Review for ADSK, SRCL, TFSL, OPWV, TSRA and ONTY
Oncothyreon announces closing of $15.0 million registered direct financing
Oncothyreon announces webcast of second quarter 2009 financial results conference call
Oncothyreon announces commitments to purchase $15.0 million of company securities in a registered direct financing
Stocks to Watch for Tuesday, August 4, 2009: MNGA -- MagneGas Receives Its Most Significant Independent Media Attention to Date in the Form of a Feature Article in Welding Journal!
Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
Oncothyreon appoints Scott Peterson as Vice President of Research and Development
Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Oncothyreon announces closing of $11.1 million registered direct financing
Oncothyreon Announces Commitments to Purchase $11.1 Million of Company Securities in a Registered Direct Financing
Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis
Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
Oncothyreon reports first quarter 2009 financial results
Oncothyreon regains compliance with NASDAQ listing requirements
Oncothyreon to present at Invest Northwest 2009
Oncothyreon to present at Invest Northwest 2009
Oncothyreon reports full year and fourth quarter 2008 financial results
Oncothyreon reports full year and fourth quarter 2008 financial results
Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
Oncothyreon to present at BIO CEO & Investor Conference 2009
Oncothyreon announces development plans and personnel changes and updates financial guidance
Oncothyreon announces development plans and personnel changes and updates financial guidance
Merck KGaA acquires manufacturing rights for Stimuvax from Oncothyreon - PR Newswire
Merck KGaA acquires manufacturing rights for Stimuvax from Oncothyreon - CNW
Oncothyreon reports third quarter 2008 financial results
Oncothyreon reports third quarter 2008 financial results
Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
Oncothyreon to present at BIO Investor Forum 2008
Oncothyreon to present at BIO Investor Forum 2008
Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
Oncothyreon announces prioritization plan for development programs
Oncothyreon announces public common stock offering
Oncothyreon announces prioritization plan for development programs
Oncothyreon announces public common stock offering
Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
Oncothyreon reports second quarter 2008 financial results
Oncothyreon reports second quarter 2008 financial results
Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Oncothyreon announces appointments to board of directors
Oncothyreon announces appointments to board of directors
Stimuvax Phase 1/2 survival data support prior results
Oncothyreon to receive milestone payment - Jun 2 2008 12:51AM
Oncothyreon to receive milestone payment - May 27 2008 12:53AM
Oncothyreon to receive milestone payment - May 26 2008 10:28PM
Oncothyreon Reports First Quarter 2008 Financial Results - Jun 2 2008 12:51AM
Oncothyreon files investigational new drug application for PX-866 oncology compound - Jun 2 2008 12:51AM
Data for Oncothyreon's PX-12 and PX-866 presented at AACR Annual Meeting
Oncothyreon's PX-478 enhances antitumor effects of radiation therapy in preclinical models of pancreatic and brain cancer
Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Oncothyreon announces effectiveness of shelf registration statement